Phase 2 N=14 A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival — 43 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Multiple Myeloma
Primary: Phase 1: Percentage of Participants With Overall Response Rate (ORR) — 100.0; 100.0; 75.0; 66.7 Percentage of participants
Phase 2 N=238 Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
Bipolar Disorder
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -8.91; -15.02 score on a scale — p=<0.0001
Phase 2 N=125 A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Ovarian Neoplasms
Primary: Progression-Free Survival (PFS) — 18.1; 17.3 weeks — p=0.8049
Phase 2 N=148 A Study of Olaratumab in Soft Tissue Sarcoma
Sarcoma, Soft Tissue
Primary: Progression-free Survival (PFS) — 6.6; 4.1 Month — p=0.0615
Phase 2 N=37 ATX-MS-1467 in Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans — 7.4; -2.4 lesions
Phase 2 N=87 Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase — 0.3; -19.4; 28.5; -49.4 percent change — p=<0.0001
Phase 2 N=67 Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Activities of Daily Living (ADL) at 18 Months — -11.58; -13.45 units on a scale — p=0.82
Phase 2 N=72 Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Primary: Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase — 0; 0; 11.1 Percentage of Participants
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 2 N=262 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393
Phase 2 N=10 UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Multiple Myeloma
Primary: Therapeutic Efficacy — 1 Participants
Phase 2 N=23 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
Carcinoma，Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days
Phase 2 N=22 A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Parkinson's Disease
Primary: Change in Velocity — 0.03; 0.05 m/s
Phase 2 N=28 Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
AIDS
Primary: Number of Subjects With Frequency of Cluster of Differentiation 8 (CD8+) T Cells Expressing at Least One Cytokine to at Least 1, 2, 3 or All 4 Antigens — 1; 3; 0; 0…